EDIT (Editas Medicine) Moat Score: 5/10 (As of Jun. 28, 2026)


EDIT Editas Medicine Inc EDIT
51 GF Score
Price $2.86
GF Value $1.92
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Editas Medicine Moat Score?

Editas Medicine EDIT +4.01% 51 Moat Score is 5 as of Jun. 28, 2026. GuruFocus rates EDIT with a GF Score™ of 51/100 and a GF Value™ of $1.92 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,402 Biotechnology companies, Editas Medicine ranks better than 96.72% on this metric.

Editas Medicine has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Editas Medicine has Narrow Moat: Editas Medicine Inc has valuable intellectual property in gene editing technology, providing some competitive edge. However, the biotech sector's rapid innovation and competition limit its moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Editas Medicine might have Narrow Moat - Solid narrow moat.

Editas Medicine  (NAS:EDIT) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Editas Medicine Moat Score Related Terms

EDIT vs PRTA, XOMA, FDMT: Moat Score Comparison

For the Biotechnology subindustry, Editas Medicine's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Editas Medicine Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Editas Medicine's Moat Score distribution charts can be found below:

* The bar in red indicates where Editas Medicine's Moat Score falls into.


EDIT
51GF Score
Editas Medicine Inc EDIT
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Editas Medicine (EDIT) has a Moat Score of 5 as of Jun. 28, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Editas Medicine ranks #46 out of 1402 companies in the Biotechnology industry, placing it in the top 3.3%.
Is Editas Medicine's Moat Score too high?
Editas Medicine's current Moat Score is 5. The Biotechnology industry median Moat Score is 2.00. Editas Medicine's value of 5 is 150% above this industry median. Based on the distribution chart, Editas Medicine ranks #46 out of 1402 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Editas Medicine has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Editas Medicine's Moat Score compare to PRTA and XOMA?
According to the Biotechnology industry distribution chart, Editas Medicine ranks #46 out of 1402 companies for Moat Score. This places Editas Medicine in the top 3% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Editas Medicine's value of 5 is 150% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,402 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Editas Medicine's current Moat Score of 5 is 150% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Editas Medicine's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Editas Medicine stock overvalued right now?
Based on GuruFocus' analysis, Editas Medicine (EDIT) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.92, compared to a current price of $2.86 — trading 49% above its estimated fair value. The current Moat Score is 5 and 150% above the Biotechnology industry median of 2.00. Editas Medicine's overall GF Score™ is 51/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Editas Medicine (EDIT), the current Moat Score is 5 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Editas Medicine (EDIT) Overvalued in 2026?

Based on GuruFocus' analysis, Editas Medicine stock appears to be overvalued. The current stock price of $2.86 is trading 49% above its estimated GF Value™ of $1.92. GuruFocus considers Editas Medicine to be Significantly Overvalued.

Key valuation signals for EDIT:

  • Moat Score: 5
  • GF Value™: $1.92 vs. price of $2.86 (49% above fair value)
  • GF Score™: 51/100 with 8 warning signs
  • Industry Position: 150% above the Biotechnology median (#46 of 1402)

No single metric tells the full story. See the EDIT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Editas Medicine Business Description

Other Exchanges 0IFK:UK8EM:Germany
Address 11 Hurley Street, Cambridge, MA, USA, 02141
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
51GF Score

Get the complete analysis for EDIT

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.86
Price
$1.92
GF Value